HU201906B
(en)
*
|
1987-03-04 |
1991-01-28 |
Sandoz Ag |
Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
|
WO1995028177A1
(fr)
*
|
1994-04-15 |
1995-10-26 |
Meiji Seika Kaisha, Ltd. |
Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition
|
IL130528A
(en)
|
1996-12-18 |
2004-12-15 |
Teva Pharma |
Aminoindan derivatives, pharmaceutical compositions comprising them and uses thereof
|
US6251938B1
(en)
|
1996-12-18 |
2001-06-26 |
Teva Pharmaceutical Industries, Ltd., |
Phenylethylamine derivatives
|
DE69725467T2
(de)
*
|
1996-12-18 |
2004-07-22 |
Teva Pharmaceutical Industries Ltd. |
Phenylethylamin-derivate
|
GB9800526D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Ciba Geigy Ag |
Organic compounds
|
US6316023B1
(en)
*
|
1998-01-12 |
2001-11-13 |
Novartis Ag |
TTS containing an antioxidant
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
ES2237163T3
(es)
|
1998-10-01 |
2005-07-16 |
Novartis Ag |
Nuevas formulaciones orales de revastigmina de liberacion controlada.
|
US20040209849A1
(en)
*
|
1998-11-27 |
2004-10-21 |
Sanochemia Pharmazeutika Aktiengesellschaft |
Use of effectors of the central cholinergic nervous system for treatment of delirium
|
WO2000033840A1
(fr)
*
|
1998-12-11 |
2000-06-15 |
Bonnie Davis |
Utilisation d'inhibiteurs d'acetylcholine esterase pour la modulation de l'axe hypothalamo-hypophyso-gonadique
|
GB9923045D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Novartis Ag |
New oral formulations
|
US6534541B1
(en)
*
|
1999-10-19 |
2003-03-18 |
Novartis Ag |
Treatment of ocular disorders
|
AU5702201A
(en)
*
|
2000-04-13 |
2001-10-30 |
Mayo Foundation |
Abeta<sub>42</sub> lowering agents
|
US20040010038A1
(en)
*
|
2002-02-27 |
2004-01-15 |
Eran Blaugrund |
Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
|
CZ293014B6
(cs)
*
|
2002-10-24 |
2004-01-14 |
Léčiva, A.S. |
Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
|
GEP20094759B
(en)
*
|
2002-10-24 |
2009-08-25 |
Merz Pharma Gmbh & Co Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
EP1603548A4
(fr)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
Composition et methode de traitement de troubles neurodegeneratifs
|
US7521481B2
(en)
*
|
2003-02-27 |
2009-04-21 |
Mclaurin Joanne |
Methods of preventing, treating and diagnosing disorders of protein aggregation
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
CA2543322A1
(fr)
*
|
2003-10-21 |
2005-05-12 |
Sention, Inc. |
Esters de carbamoyle inhibant la cholinesterase et liberant des agents pharmacologiquement actifs
|
GB2409453A
(en)
|
2003-12-24 |
2005-06-29 |
Generics |
Process for the preparation of aminoalkyl phenylcarbamates
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
WO2005108683A1
(fr)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Placages pour parois, murs de soutenement et analogues
|
US20080045500A1
(en)
*
|
2004-07-01 |
2008-02-21 |
Eisai R&D Management Co., Ltd. |
Nerve Regeneration Stimulator
|
WO2006020853A2
(fr)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
|
WO2006020852A2
(fr)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
|
WO2006020850A2
(fr)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
|
EP1856036B1
(fr)
*
|
2004-11-08 |
2016-12-14 |
Emcure Pharmaceuticals Limited |
Procede efficace de preparation de (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
|
GB0507298D0
(en)
|
2005-04-11 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
BRPI0613611A2
(pt)
*
|
2005-07-22 |
2011-01-18 |
Myriad Genetics Inc |
formulações de alta concentração de fármaco e formas de dosagens
|
ES2267399B1
(es)
|
2005-08-04 |
2008-02-01 |
Ragactives, S.L. |
Procedimiento para la obtencion de carbamatos de fenilo.
|
ATE546202T1
(de)
|
2005-09-15 |
2012-03-15 |
Sony Computer Entertainment Inc |
Kabelloser videospielcontroller und verfahren zum betreiben des kabellosen videospielcontrollers
|
TWI389709B
(zh)
|
2005-12-01 |
2013-03-21 |
Novartis Ag |
經皮治療系統
|
BRPI0620659A2
(pt)
*
|
2005-12-09 |
2017-10-31 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
|
TW200744576A
(en)
*
|
2006-02-24 |
2007-12-16 |
Teva Pharma |
Propargylated aminoindans, processes for preparation, and uses thereof
|
US7767843B2
(en)
*
|
2006-03-02 |
2010-08-03 |
Apotex Pharmachem Inc. |
Process for the preparation of phenylcarbamates
|
EP2046119A2
(fr)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Traitement de troubles psychiatriques
|
WO2008020452A1
(fr)
*
|
2006-08-17 |
2008-02-21 |
Alembic Limited |
Procédé pour la préparation de rivastigmine amélioré
|
WO2008037433A1
(fr)
|
2006-09-29 |
2008-04-03 |
Synthon B.V. |
Procédé de fabrication de carbamates d'aminoalkylphényle et intermédiaires de cette fabrication
|
EP2086538B1
(fr)
|
2006-10-27 |
2012-03-14 |
Medivation Neurology, Inc. |
Combinaison de thérapies pour le traitement de la maladie d'alzheimer avec dimebon et donepezil
|
EP1942100A1
(fr)
*
|
2007-01-04 |
2008-07-09 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Formes amorphes et cristallines dýhydrogénotartrate de rivastigmine
|
MX2009008288A
(es)
*
|
2007-02-02 |
2009-12-01 |
Colucid Pharmaceuticals Inc |
Compuestos que inhiben la colinesterasa.
|
EP1980552A3
(fr)
|
2007-04-10 |
2008-10-29 |
Dr. Reddy's Laboratories Ltd. |
Processus pour la préparation de rivastigmine ou sel correspondant
|
WO2008124969A1
(fr)
*
|
2007-04-16 |
2008-10-23 |
Topharman Shanghai Co., Ltd. |
Méthode de préparation de rivastigmine et de ses intermédiaires
|
US7884121B2
(en)
*
|
2007-06-11 |
2011-02-08 |
Apotex Pharmachem Inc. |
Process for the preparation of phenylcarbamates
|
EP2182938A2
(fr)
*
|
2007-07-18 |
2010-05-12 |
Colucid Pharmaceuticals, Inc. |
Procédés pour favoriser la veille
|
US8593728B2
(en)
*
|
2009-02-19 |
2013-11-26 |
Toyota Motor Engineering & Manufacturing North America, Inc. |
Multilayer photonic structures
|
US20090082436A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched rivastigmine
|
US8324429B2
(en)
*
|
2008-01-10 |
2012-12-04 |
Shanghai Institute Of Pharmaceutical Industry |
Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
|
US8420846B2
(en)
|
2008-08-25 |
2013-04-16 |
Jubilant Life Sciences Limited |
Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
|
US20100087768A1
(en)
*
|
2008-10-02 |
2010-04-08 |
Forlano Paula |
Transdermal drug delivery system for liquid active ingredient
|
GB0823554D0
(en)
*
|
2008-12-24 |
2009-01-28 |
Novartis Ag |
Process for the preparation of optically active compounds using transfer hydrogenation
|
CN101823970B
(zh)
*
|
2009-03-03 |
2013-05-08 |
江苏恩华药业股份有限公司 |
卡巴拉汀及其中间体的合成方法
|
WO2011076621A2
(fr)
|
2009-12-22 |
2011-06-30 |
Acino Ag |
Système thérapeutique transdermique servant à administrer de la rivastigmine ou ses dérivés
|
US10076502B2
(en)
|
2009-12-22 |
2018-09-18 |
Luye Pharma Ag |
Transdermal therapeutic system for administering rivastigmine or derivatives thereof
|
ES2363395B1
(es)
*
|
2010-01-20 |
2012-02-23 |
Farmalider, S.A. |
Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
|
CN102905532A
(zh)
|
2010-02-09 |
2013-01-30 |
约翰斯.霍普金斯大学 |
用于改善认知功能的方法和组合物
|
MX2012011340A
(es)
|
2010-03-29 |
2012-11-16 |
Novartis Ag |
Composicion que comprende el peptido amiloide beta 1-6acoplado a una particula similar a virus y un auxiliar.
|
WO2011151359A1
(fr)
|
2010-06-02 |
2011-12-08 |
Noscira, S.A. |
Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
|
WO2011151669A1
(fr)
|
2010-06-02 |
2011-12-08 |
Jubilant Life Sciences Limited |
Procédé de production d'un isomère énantiomériquement enrichi d'un dérivé du 3-(1-aminoéthyle) phényle et son utilisation pour produire de la rivastigmine ou son sel pharmaceutiquement acceptable
|
EP2582799B1
(fr)
|
2010-06-17 |
2017-12-20 |
Codexis, Inc. |
Biocatalyseurs et procédés pour la synthèse de (s)-3-(1-aminoéthyl)-phénol
|
NO3034079T3
(fr)
|
2010-11-15 |
2018-06-09 |
|
|
RS54173B1
(en)
|
2010-12-14 |
2015-12-31 |
Acino Ag |
TRANSDERMAL THERAPY SYSTEM FOR ACTIVE SUBSTANCE
|
CN102786441B
(zh)
|
2011-05-18 |
2013-11-13 |
浙江海正药业股份有限公司 |
利凡斯的明的制备方法、其中间体以及中间体的制备方法
|
EP2711002A4
(fr)
|
2011-05-20 |
2014-10-29 |
Sk Chemicals Co Ltd |
Timbre contenant de la rivastigmine
|
AR082640A1
(es)
*
|
2011-08-25 |
2012-12-19 |
Amarin Technologies S A |
Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
|
EP2752188B1
(fr)
|
2011-08-31 |
2020-05-06 |
Toyo Ink Sc Holdings Co., Ltd. |
Timbre transdermique
|
CN103073456B
(zh)
*
|
2011-10-26 |
2014-03-19 |
连云港润众制药有限公司 |
重酒石酸卡巴拉汀中间体的制备方法
|
EP2594261A1
(fr)
|
2011-11-18 |
2013-05-22 |
Labtec GmbH |
Composition pour administration transdermique de rivastigmine
|
WO2013142339A1
(fr)
|
2012-03-23 |
2013-09-26 |
Novartis Ag |
Système thérapeutique transdermique et procédé associé
|
ES2449215B1
(es)
*
|
2012-09-17 |
2014-07-14 |
Galenicum Health S.L. |
Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
|
KR20140038237A
(ko)
|
2012-09-20 |
2014-03-28 |
에스케이케미칼주식회사 |
리바스티그민의 안정성이 개선된 의약품
|
CA2891122C
(fr)
|
2012-11-14 |
2021-07-20 |
The Johns Hopkins University |
Methodes et compositions pour le traitement de la schizophrenie
|
CN103896787A
(zh)
*
|
2012-12-26 |
2014-07-02 |
江苏康倍得药业有限公司 |
一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
|
WO2014111790A2
(fr)
|
2013-01-15 |
2014-07-24 |
Zydus Technologies Limited |
Système d'administration de médicament pharmaceutique transdermique stable comprenant de la rivastigmine
|
WO2014144663A1
(fr)
|
2013-03-15 |
2014-09-18 |
The Johns Hopkins University |
Procédés et compositions pour améliorer la fonction cognitive
|
WO2014144801A1
(fr)
|
2013-03-15 |
2014-09-18 |
Agenebio Inc. |
Procédés et compositions pour améliorer la fonction cognitive
|
CN103319374B
(zh)
*
|
2013-06-09 |
2015-04-22 |
无锡佰翱得生物科学有限公司 |
一种(s)-卡巴拉汀的不对称合成方法
|
AU2014307803A1
(en)
|
2013-08-16 |
2016-03-10 |
Universiteit Maastricht |
Treatment of cognitive impairment with PDE4 inhibitor
|
MX2016007808A
(es)
|
2013-12-20 |
2016-09-07 |
Agenebio Inc |
Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo.
|
EA034167B8
(ru)
|
2015-05-22 |
2021-04-27 |
Эйджинбайо, Инк. |
Фармацевтические композиции леветирацетама пролонгированного высвобождения
|
CN113264939A
(zh)
|
2015-06-19 |
2021-08-17 |
艾吉因生物股份有限公司 |
用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
WO2019246300A1
(fr)
|
2018-06-19 |
2019-12-26 |
Agenebio, Inc. |
Dérivés de benzodiazépine, compositions, et méthodes de traitement de déficience cognitive
|
KR20200035359A
(ko)
|
2018-09-26 |
2020-04-03 |
캐딜라 파마슈티클즈 리미티드 |
리바스티그민 제조용 중간체의 합성
|
WO2024039886A1
(fr)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
|